[
    [
        {
            "time": "2019-10-14",
            "original_text": "【民生医药|周报】10/14：生物药和外包板块表现优异，关注业绩高增长标的",
            "features": {
                "keywords": [
                    "泰格医药",
                    "前三季",
                    "净利润",
                    "增长",
                    "63%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物药",
                    "外包"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|周报】10/14：生物药和外包板块表现优异，关注业绩高增长标的",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-10-15",
            "original_text": "泰格医药：前三季度净利预增64%-70%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "前三季度",
                    "净利",
                    "预增",
                    "64%-70%"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：前三季度净利预增64%-70%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-10-16",
            "original_text": "泰格医药：第三季度净利润预增70%-90%",
            "features": {
                "keywords": [
                    "泰格医药",
                    "第三季度",
                    "净利润",
                    "预增",
                    "70%-90%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：第三季度净利润预增70%-90%",
                "Correlation": 10,
                "Sentiment": 10,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 10,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2019-10-17",
            "original_text": "泰格医药：预计核心业务持续高景气，买入评级",
            "features": {
                "keywords": [
                    "泰格医药",
                    "核心业务",
                    "高景气",
                    "买入评级"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药：预计核心业务持续高景气，买入评级",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2019-10-18",
            "original_text": "【民生医药|季报点评】泰格医药：Q3单季超高增长，多业务拐点趋势或延续",
            "features": {
                "keywords": [
                    "泰格医药",
                    "Q3",
                    "单季",
                    "超高增长",
                    "多业务拐点"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【民生医药|季报点评】泰格医药：Q3单季超高增长，多业务拐点趋势或延续",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]